APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Treating Hyperuricemia

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Drugs for Treating Hyperuricemia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025192 pages

Choose your research edition.

Industry ResearchDrugs for Treating Hyperuricemia Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Treating Hyperuricemia Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Drugs for Treating Hyperuricemia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Treating Hyperuricemia Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Treating Hyperuricemia Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Drugs for Treating Hyperuricemia market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Drugs for Treating Hyperuricemia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for Treating Hyperuricemia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Treating Hyperuricemia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Drugs for Treating Hyperuricemia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Drugs for Treating Hyperuricemia include Teva, 三和化学研究所, Sanofi, Towa Pharmaceutical, Toa Eiyo, Takeda Pharmaceuticals, Mylan Pharmaceuticals, Mochida Pharmaceutical and Lannett Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Drugs for Treating Hyperuricemia market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Treating Hyperuricemia and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Treating Hyperuricemia sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for Treating Hyperuricemia market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for Treating Hyperuricemia Segment by Company

Teva

三和化学研究所

Sanofi

Towa Pharmaceutical

Toa Eiyo

Takeda Pharmaceuticals

Mylan Pharmaceuticals

Mochida Pharmaceutical

Lannett Company

Horizo​​n Therapeutics

GSK

Fuji Yakuhin

AstraZeneca

Drugs for Treating Hyperuricemia Segment by Type

Urate-stimulating Excretion Agents

Uric Acid Production Inhibitors

Other

Drugs for Treating Hyperuricemia Segment by Application

Retail Pharmacies

Hospitals and Clinics

Other

Drugs for Treating Hyperuricemia Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Treating Hyperuricemia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Treating Hyperuricemia and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Treating Hyperuricemia.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for Treating Hyperuricemia market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Drugs for Treating Hyperuricemia manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Drugs for Treating Hyperuricemia in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Drugs for Treating Hyperuricemia in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Drugs for Treating Hyperuricemia Industry Trends Table 2. Drugs for Treating Hyperuricemia Industry Drivers Table 3. Drugs for Treating Hyperuricemia Industry Opportunities and Challenges Table 4. Drugs for Treating Hyperuricemia Industry Restraints Table 5. Global Drugs for Treating Hyperuricemia Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Drugs for Treating Hyperuricemia Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Drugs for Treating Hyperuricemia Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Drugs for Treating Hyperuricemia Sales Market Share by Manufacturers Table 9. Global Drugs for Treating Hyperuricemia Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Drugs for Treating Hyperuricemia Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Drugs for Treating Hyperuricemia Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Drugs for Treating Hyperuricemia Manufacturers, Product Type & Application Table 13. Global Drugs for Treating Hyperuricemia Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for Treating Hyperuricemia by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Urate-stimulating Excretion Agents Table 17. Major Manufacturers of Uric Acid Production Inhibitors Table 18. Major Manufacturers of Other Table 19. Global Drugs for Treating Hyperuricemia Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Drugs for Treating Hyperuricemia Sales by Type (2021-2026) & (K Units) Table 21. Global Drugs for Treating Hyperuricemia Sales by Type (2027-2032) & (K Units) Table 22. Global Drugs for Treating Hyperuricemia Sales Market Share by Type (2021-2026) Table 23. Global Drugs for Treating Hyperuricemia Sales Market Share by Type (2027-2032) Table 24. Global Drugs for Treating Hyperuricemia Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Drugs for Treating Hyperuricemia Revenue by Type (2021-2026) & (K Units) Table 26. Global Drugs for Treating Hyperuricemia Revenue by Type (2027-2032) & (K Units) Table 27. Global Drugs for Treating Hyperuricemia Revenue Market Share by Type (2021-2026) Table 28. Global Drugs for Treating Hyperuricemia Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Retail Pharmacies Table 30. Major Manufacturers of Hospitals and Clinics Table 31. Major Manufacturers of Other Table 32. Global Drugs for Treating Hyperuricemia Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Drugs for Treating Hyperuricemia Sales by Application (2021-2026) & (K Units) Table 34. Global Drugs for Treating Hyperuricemia Sales by Application (2027-2032) & (K Units) Table 35. Global Drugs for Treating Hyperuricemia Sales Market Share by Application (2021-2026) Table 36. Global Drugs for Treating Hyperuricemia Sales Market Share by Application (2027-2032) Table 37. Global Drugs for Treating Hyperuricemia Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Drugs for Treating Hyperuricemia Revenue by Application (2021-2026) & (K Units) Table 39. Global Drugs for Treating Hyperuricemia Revenue by Application (2027-2032) & (K Units) Table 40. Global Drugs for Treating Hyperuricemia Revenue Market Share by Application (2021-2026) Table 41. Global Drugs for Treating Hyperuricemia Revenue Market Share by Application (2027-2032) Table 42. Global Drugs for Treating Hyperuricemia Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Drugs for Treating Hyperuricemia Sales by Region (2021-2026) & (K Units) Table 44. Global Drugs for Treating Hyperuricemia Sales Market Share by Region (2021-2026) Table 45. Global Drugs for Treating Hyperuricemia Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Drugs for Treating Hyperuricemia Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Drugs for Treating Hyperuricemia Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Drugs for Treating Hyperuricemia Sales by Country (2021-2026) & (K Units) Table 49. North America Drugs for Treating Hyperuricemia Sales by Country (2027-2032) & (K Units) Table 50. Europe Drugs for Treating Hyperuricemia Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Drugs for Treating Hyperuricemia Sales by Country (2021-2026) & (K Units) Table 52. Europe Drugs for Treating Hyperuricemia Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Drugs for Treating Hyperuricemia Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Drugs for Treating Hyperuricemia Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Drugs for Treating Hyperuricemia Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Drugs for Treating Hyperuricemia Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Drugs for Treating Hyperuricemia Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Drugs for Treating Hyperuricemia Sales by Country (2027-2032) & (K Units) Table 59. Global Drugs for Treating Hyperuricemia Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Drugs for Treating Hyperuricemia Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Drugs for Treating Hyperuricemia Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Drugs for Treating Hyperuricemia Revenue Market Share by Region (2021-2026) Table 63. Global Drugs for Treating Hyperuricemia Revenue Market Share by Region (2027-2032) Table 64. Teva Company Information Table 65. Teva Business Overview Table 66. Teva Drugs for Treating Hyperuricemia Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Teva Drugs for Treating Hyperuricemia Product Portfolio Table 68. Teva Recent Development Table 69. 三和化学研究所 Company Information Table 70. 三和化学研究所 Business Overview Table 71. 三和化学研究所 Drugs for Treating Hyperuricemia Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. 三和化学研究所 Drugs for Treating Hyperuricemia Product Portfolio Table 73. 三和化学研究所 Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Drugs for Treating Hyperuricemia Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Sanofi Drugs for Treating Hyperuricemia Product Portfolio Table 78. Sanofi Recent Development Table 79. Towa Pharmaceutical Company Information Table 80. Towa Pharmaceutical Business Overview Table 81. Towa Pharmaceutical Drugs for Treating Hyperuricemia Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Towa Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolio Table 83. Towa Pharmaceutical Recent Development Table 84. Toa Eiyo Company Information Table 85. Toa Eiyo Business Overview Table 86. Toa Eiyo Drugs for Treating Hyperuricemia Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Toa Eiyo Drugs for Treating Hyperuricemia Product Portfolio Table 88. Toa Eiyo Recent Development Table 89. Takeda Pharmaceuticals Company Information Table 90. Takeda Pharmaceuticals Business Overview Table 91. Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolio Table 93. Takeda Pharmaceuticals Recent Development Table 94. Mylan Pharmaceuticals Company Information Table 95. Mylan Pharmaceuticals Business Overview Table 96. Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolio Table 98. Mylan Pharmaceuticals Recent Development Table 99. Mochida Pharmaceutical Company Information Table 100. Mochida Pharmaceutical Business Overview Table 101. Mochida Pharmaceutical Drugs for Treating Hyperuricemia Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Mochida Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolio Table 103. Mochida Pharmaceutical Recent Development Table 104. Lannett Company Company Information Table 105. Lannett Company Business Overview Table 106. Lannett Company Drugs for Treating Hyperuricemia Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Lannett Company Drugs for Treating Hyperuricemia Product Portfolio Table 108. Lannett Company Recent Development Table 109. Horizo​​n Therapeutics Company Information Table 110. Horizo​​n Therapeutics Business Overview Table 111. Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Product Portfolio Table 113. Horizo​​n Therapeutics Recent Development Table 114. GSK Company Information Table 115. GSK Business Overview Table 116. GSK Drugs for Treating Hyperuricemia Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. GSK Drugs for Treating Hyperuricemia Product Portfolio Table 118. GSK Recent Development Table 119. Fuji Yakuhin Company Information Table 120. Fuji Yakuhin Business Overview Table 121. Fuji Yakuhin Drugs for Treating Hyperuricemia Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Fuji Yakuhin Drugs for Treating Hyperuricemia Product Portfolio Table 123. Fuji Yakuhin Recent Development Table 124. AstraZeneca Company Information Table 125. AstraZeneca Business Overview Table 126. AstraZeneca Drugs for Treating Hyperuricemia Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. AstraZeneca Drugs for Treating Hyperuricemia Product Portfolio Table 128. AstraZeneca Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Drugs for Treating Hyperuricemia Distributors List Table 132. Drugs for Treating Hyperuricemia Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Drugs for Treating Hyperuricemia Product Image Figure 2. Global Drugs for Treating Hyperuricemia Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Treating Hyperuricemia Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Treating Hyperuricemia Sales (2021-2032) & (K Units) Figure 5. Global Drugs for Treating Hyperuricemia Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Drugs for Treating Hyperuricemia Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Urate-stimulating Excretion Agents Image Figure 9. Uric Acid Production Inhibitors Image Figure 10. Other Image Figure 11. Global Drugs for Treating Hyperuricemia Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Drugs for Treating Hyperuricemia Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Drugs for Treating Hyperuricemia Sales Market Share by Type (2021-2032) Figure 14. Global Drugs for Treating Hyperuricemia Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Drugs for Treating Hyperuricemia Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Drugs for Treating Hyperuricemia Revenue Market Share by Type (2021-2032) Figure 17. Retail Pharmacies Image Figure 18. Hospitals and Clinics Image Figure 19. Other Image Figure 20. Global Drugs for Treating Hyperuricemia Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Drugs for Treating Hyperuricemia Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Drugs for Treating Hyperuricemia Sales Market Share by Application (2021-2032) Figure 23. Global Drugs for Treating Hyperuricemia Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Drugs for Treating Hyperuricemia Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Drugs for Treating Hyperuricemia Revenue Market Share by Application (2021-2032) Figure 26. North America Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Drugs for Treating Hyperuricemia Sales Market Share by Country (2021-2032) Figure 28. U.S. Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Drugs for Treating Hyperuricemia Sales Market Share by Country (2021-2032) Figure 33. Germany Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Drugs for Treating Hyperuricemia Sales Market Share by Country (2021-2032) Figure 40. China Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Drugs for Treating Hyperuricemia Sales Market Share by Country (2021-2032) Figure 48. Brazil Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Drugs for Treating Hyperuricemia Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Drugs for Treating Hyperuricemia Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Drugs for Treating Hyperuricemia Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Drugs for Treating Hyperuricemia Revenue (2021-2032) & (US$ Million) Figure 59. North America Drugs for Treating Hyperuricemia Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Drugs for Treating Hyperuricemia Revenue (2021-2032) & (US$ Million) Figure 61. Europe Drugs for Treating Hyperuricemia Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Drugs for Treating Hyperuricemia Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Drugs for Treating Hyperuricemia Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Drugs for Treating Hyperuricemia Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Drugs for Treating Hyperuricemia Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Drugs for Treating Hyperuricemia Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Drugs for Treating Hyperuricemia Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Urate-stimulating Excretion Agents
  • Uric Acid Production Inhibitors
  • Other
Applications
  • Retail Pharmacies
  • Hospitals and Clinics
  • Other
Companies covered
  • Teva
  • 三和化学研究所
  • Sanofi
  • Towa Pharmaceutical
  • Toa Eiyo
  • Takeda Pharmaceuticals
  • Mylan Pharmaceuticals
  • Mochida Pharmaceutical
  • Lannett Company
  • Horizo​​n Therapeutics
  • GSK
  • Fuji Yakuhin
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs for Treating Hyperuricemia Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs for Treating Hyperuricemia Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Drugs for Treating Hyperuricemia Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Drugs for Treating Hyperuricemia Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Drugs for Treating Hyperuricemia Market Dynamics
  1. 2.1 Drugs for Treating Hyperuricemia Industry Trends
  2. 2.2 Drugs for Treating Hyperuricemia Industry Drivers
  3. 2.3 Drugs for Treating Hyperuricemia Industry Opportunities and Challenges
  4. 2.4 Drugs for Treating Hyperuricemia Industry Restraints
3 Drugs for Treating Hyperuricemia Market by Manufacturers
  1. 3.1 Global Drugs for Treating Hyperuricemia Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Drugs for Treating Hyperuricemia Sales by Manufacturers (2021-2026)
  3. 3.3 Global Drugs for Treating Hyperuricemia Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Drugs for Treating Hyperuricemia Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Drugs for Treating Hyperuricemia Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Drugs for Treating Hyperuricemia Manufacturers, Product Type & Application
  7. 3.7 Global Drugs for Treating Hyperuricemia Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Drugs for Treating Hyperuricemia Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Drugs for Treating Hyperuricemia Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Drugs for Treating Hyperuricemia Tier 1, Tier 2, and Tier 3
4 Drugs for Treating Hyperuricemia Market by Type
  1. 4.1 Drugs for Treating Hyperuricemia Type Introduction
  2. 4.1.1 Urate-stimulating Excretion Agents
  3. 4.1.2 Uric Acid Production Inhibitors
  4. 4.1.3 Other
  5. 4.2 Global Drugs for Treating Hyperuricemia Sales by Type
  6. 4.2.1 Global Drugs for Treating Hyperuricemia Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drugs for Treating Hyperuricemia Sales by Type (2021-2032)
  8. 4.2.3 Global Drugs for Treating Hyperuricemia Sales Market Share by Type (2021-2032)
  9. 4.3 Global Drugs for Treating Hyperuricemia Revenue by Type
  10. 4.3.1 Global Drugs for Treating Hyperuricemia Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Drugs for Treating Hyperuricemia Revenue by Type (2021-2032)
  12. 4.3.3 Global Drugs for Treating Hyperuricemia Revenue Market Share by Type (2021-2032)
5 Drugs for Treating Hyperuricemia Market by Application
  1. 5.1 Drugs for Treating Hyperuricemia Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospitals and Clinics
  4. 5.1.3 Other
  5. 5.2 Global Drugs for Treating Hyperuricemia Sales by Application
  6. 5.2.1 Global Drugs for Treating Hyperuricemia Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for Treating Hyperuricemia Sales by Application (2021-2032)
  8. 5.2.3 Global Drugs for Treating Hyperuricemia Sales Market Share by Application (2021-2032)
  9. 5.3 Global Drugs for Treating Hyperuricemia Revenue by Application
  10. 5.3.1 Global Drugs for Treating Hyperuricemia Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Drugs for Treating Hyperuricemia Revenue by Application (2021-2032)
  12. 5.3.3 Global Drugs for Treating Hyperuricemia Revenue Market Share by Application (2021-2032)
6 Global Drugs for Treating Hyperuricemia Sales by Region
  1. 6.1 Global Drugs for Treating Hyperuricemia Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Treating Hyperuricemia Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for Treating Hyperuricemia Sales by Region (2021-2026)
  4. 6.2.2 Global Drugs for Treating Hyperuricemia Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs for Treating Hyperuricemia Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Drugs for Treating Hyperuricemia Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Drugs for Treating Hyperuricemia Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Drugs for Treating Hyperuricemia Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Drugs for Treating Hyperuricemia Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Drugs for Treating Hyperuricemia Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Drugs for Treating Hyperuricemia Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Drugs for Treating Hyperuricemia Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Drugs for Treating Hyperuricemia Revenue by Region
  1. 7.1 Global Drugs for Treating Hyperuricemia Revenue by Region
  2. 7.1.1 Global Drugs for Treating Hyperuricemia Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Drugs for Treating Hyperuricemia Revenue by Region (2021-2026)
  4. 7.1.3 Global Drugs for Treating Hyperuricemia Revenue by Region (2027-2032)
  5. 7.1.4 Global Drugs for Treating Hyperuricemia Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Drugs for Treating Hyperuricemia Revenue (2021-2032)
  8. 7.2.2 North America Drugs for Treating Hyperuricemia Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Drugs for Treating Hyperuricemia Revenue (2021-2032)
  11. 7.3.2 Europe Drugs for Treating Hyperuricemia Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Drugs for Treating Hyperuricemia Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Drugs for Treating Hyperuricemia Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Drugs for Treating Hyperuricemia Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Drugs for Treating Hyperuricemia Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Drugs for Treating Hyperuricemia Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Drugs for Treating Hyperuricemia Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 三和化学研究所
  8. 8.2.1 三和化学研究所 Company Information
  9. 8.2.2 三和化学研究所 Business Overview
  10. 8.2.3 三和化学研究所 Drugs for Treating Hyperuricemia Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 三和化学研究所 Drugs for Treating Hyperuricemia Product Portfolio
  12. 8.2.5 三和化学研究所 Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Drugs for Treating Hyperuricemia Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Drugs for Treating Hyperuricemia Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Towa Pharmaceutical
  20. 8.4.1 Towa Pharmaceutical Company Information
  21. 8.4.2 Towa Pharmaceutical Business Overview
  22. 8.4.3 Towa Pharmaceutical Drugs for Treating Hyperuricemia Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Towa Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolio
  24. 8.4.5 Towa Pharmaceutical Recent Developments
  25. 8.5 Toa Eiyo
  26. 8.5.1 Toa Eiyo Company Information
  27. 8.5.2 Toa Eiyo Business Overview
  28. 8.5.3 Toa Eiyo Drugs for Treating Hyperuricemia Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Toa Eiyo Drugs for Treating Hyperuricemia Product Portfolio
  30. 8.5.5 Toa Eiyo Recent Developments
  31. 8.6 Takeda Pharmaceuticals
  32. 8.6.1 Takeda Pharmaceuticals Company Information
  33. 8.6.2 Takeda Pharmaceuticals Business Overview
  34. 8.6.3 Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolio
  36. 8.6.5 Takeda Pharmaceuticals Recent Developments
  37. 8.7 Mylan Pharmaceuticals
  38. 8.7.1 Mylan Pharmaceuticals Company Information
  39. 8.7.2 Mylan Pharmaceuticals Business Overview
  40. 8.7.3 Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolio
  42. 8.7.5 Mylan Pharmaceuticals Recent Developments
  43. 8.8 Mochida Pharmaceutical
  44. 8.8.1 Mochida Pharmaceutical Company Information
  45. 8.8.2 Mochida Pharmaceutical Business Overview
  46. 8.8.3 Mochida Pharmaceutical Drugs for Treating Hyperuricemia Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Mochida Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolio
  48. 8.8.5 Mochida Pharmaceutical Recent Developments
  49. 8.9 Lannett Company
  50. 8.9.1 Lannett Company Company Information
  51. 8.9.2 Lannett Company Business Overview
  52. 8.9.3 Lannett Company Drugs for Treating Hyperuricemia Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Lannett Company Drugs for Treating Hyperuricemia Product Portfolio
  54. 8.9.5 Lannett Company Recent Developments
  55. 8.10 Horizo​​n Therapeutics
  56. 8.10.1 Horizo​​n Therapeutics Company Information
  57. 8.10.2 Horizo​​n Therapeutics Business Overview
  58. 8.10.3 Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Product Portfolio
  60. 8.10.5 Horizo​​n Therapeutics Recent Developments
  61. 8.11 GSK
  62. 8.11.1 GSK Company Information
  63. 8.11.2 GSK Business Overview
  64. 8.11.3 GSK Drugs for Treating Hyperuricemia Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GSK Drugs for Treating Hyperuricemia Product Portfolio
  66. 8.11.5 GSK Recent Developments
  67. 8.12 Fuji Yakuhin
  68. 8.12.1 Fuji Yakuhin Company Information
  69. 8.12.2 Fuji Yakuhin Business Overview
  70. 8.12.3 Fuji Yakuhin Drugs for Treating Hyperuricemia Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Fuji Yakuhin Drugs for Treating Hyperuricemia Product Portfolio
  72. 8.12.5 Fuji Yakuhin Recent Developments
  73. 8.13 AstraZeneca
  74. 8.13.1 AstraZeneca Company Information
  75. 8.13.2 AstraZeneca Business Overview
  76. 8.13.3 AstraZeneca Drugs for Treating Hyperuricemia Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca Drugs for Treating Hyperuricemia Product Portfolio
  78. 8.13.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for Treating Hyperuricemia Value Chain Analysis
  2. 9.1.1 Drugs for Treating Hyperuricemia Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for Treating Hyperuricemia Production Mode & Process
  6. 9.2 Drugs for Treating Hyperuricemia Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for Treating Hyperuricemia Distributors
  9. 9.2.3 Drugs for Treating Hyperuricemia Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst